These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15982879)

  • 21. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro.
    Gruszka A; Kunert-Radek J; Radek A; Pisarek H; Taylor J; Dong JZ; Culler MD; Pawlikowski M
    Life Sci; 2006 Jan; 78(7):689-93. PubMed ID: 16115652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
    Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
    J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
    Saveanu A; Jaquet P; Brue T; Barlier A
    Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional characterisation of the putative somatostatin sst2 receptor antagonist CYN 154806.
    Nunn C; Schoeffter P; Langenegger D; Hoyer D
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):1-9. PubMed ID: 12616335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2-pyridylthioureas: novel nonpeptide somatostatin agonists with SST4 selectivity.
    Liu S; Crider AM; Tang C; Ho B; Ankersen M; Stidsen CE
    Curr Pharm Des; 1999 Apr; 5(4):255-63. PubMed ID: 10101224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures.
    Djordjijevic D; Zhang J; Priam M; Viollet C; Gourdji D; Kordon C; Epelbaum J
    Endocrinology; 1998 May; 139(5):2272-7. PubMed ID: 9564833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR.
    Grace CR; Erchegyi J; Koerber SC; Reubi JC; Rivier J; Riek R
    J Med Chem; 2006 Jul; 49(15):4487-96. PubMed ID: 16854054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of the somatostatin receptor subtypes (sst) mediating the divergent, stimulatory/inhibitory actions of somatostatin on growth hormone secretion.
    Luque RM; Durán-Prado M; García-Navarro S; Gracia-Navarro F; Kineman RD; Malagón MM; Castaño JP
    Endocrinology; 2006 Jun; 147(6):2902-8. PubMed ID: 16543371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel non-peptide ligands for the somatostatin sst3 receptor.
    Moinet C; Contour-Galcéra MO; Poitout L; Morgan B; Gordon T; Rouber P; Thurieau C
    Bioorg Med Chem Lett; 2001 Apr; 11(8):991-5. PubMed ID: 11327607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spiro[1H-indene-1,4'-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst2) agonists.
    Yang L; Guo L; Pasternak A; Mosley R; Rohrer S; Birzin E; Foor F; Cheng K; Schaeffer J; Patchett AA
    J Med Chem; 1998 Jun; 41(13):2175-9. PubMed ID: 9632348
    [No Abstract]   [Full Text] [Related]  

  • 31. Binding and functional properties of the novel somatostatin analogue KE 108 at native mouse somatostatin receptors.
    Cervia D; Langenegger D; Schuepbach E; Cammalleri M; Schoeffter P; Schmid HA; Bagnoli P; Hoyer D
    Neuropharmacology; 2005 May; 48(6):881-93. PubMed ID: 15829258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatostatin receptors in Neuro2A neuroblastoma cells: operational characteristics.
    Koenig JA; Edwardson JM; Humphrey PP
    Br J Pharmacol; 1997 Jan; 120(1):45-51. PubMed ID: 9117097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis of substituted imidazopyrazines as ligands for the human somatostatin receptor subtype 5.
    Contour-Galéra MO; Poitout L; Moinet C; Morgan B; Gordon T; Roubert P; Thurieau C
    Bioorg Med Chem Lett; 2001 Mar; 11(5):741-5. PubMed ID: 11266182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chroman-4-one and chromone based somatostatin β-turn mimetics.
    Fridén-Saxin M; Seifert T; Malo M; da Silva Andersson K; Pemberton N; Dyrager C; Friberg A; Dahlén K; Wallén EA; Grøtli M; Luthman K
    Eur J Med Chem; 2016 May; 114():59-64. PubMed ID: 26974375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatostatin-14 mainly binds the somatostatin receptor subtype 2 in human neuroblastoma tumors.
    Prevost G; Veber N; Viollet C; Roubert V; Roubert P; Benard J; Eden P
    Neuroendocrinology; 1996 Feb; 63(2):188-97. PubMed ID: 9053784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
    Lesche S; Lehmann D; Nagel F; Schmid HA; Schulz S
    J Clin Endocrinol Metab; 2009 Feb; 94(2):654-61. PubMed ID: 19001514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective agonism in somatostatin receptor signaling and regulation.
    Schonbrunn A
    Mol Cell Endocrinol; 2008 May; 286(1-2):35-9. PubMed ID: 18006219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
    Siehler S; Nunn C; Zupanc GK; Hoyer D
    Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatostatin displayed on filamentous phage as a receptor-specific agonist.
    Rousch M; Lutgerink JT; Coote J; de Bruïne A; Arends JW; Hoogenboom HR
    Br J Pharmacol; 1998 Sep; 125(1):5-16. PubMed ID: 9776337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.